The headline news is that Celgene chief executive Mark Alles is heading for the door, and there’s also no room for BMS’ recently-appointed chief scientific officer Thomas Lynch in the combined ...
In a letter to BMS shareholders on Thursday, Starboard said that the merger with Celgene is “poorly conceived and ill-advised”. The activist investor said that it would vote against the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback